Vaxcyte, Inc.

97 articles about Vaxcyte, Inc.

• Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

  9/19/2023

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT.

• Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/8/2023

  Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced financial results for the second quarter ended June 30, 2023 and provided a business update.

• Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

  7/11/2023

  Vaxcyte, Inc. today announced that the ongoing Phase 2 study of VAX-24 in healthy infants is advancing to the second and final stage of the study. The independent Data Safety Monitoring Board approved advancing to the second stage of the study following the review of the safety and tolerability results from the first stage.

• Vaxcyte to Present at the 2023 Jefferies Healthcare Conference

  6/1/2023

  Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York on Thursday, June 8, 2023 at 10:30 a.m. ET / 7:30 a.m. PT.

• Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

  5/8/2023

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

• Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

  5/3/2023

  Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10, 2023, at 5:20 p.m. ET / 2:20 p.m. PT.

• Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  4/21/2023

  Vaxcyte, Inc. (Nasdaq: PCVX) announced today the closing of its previously announced underwritten public offering of 13,030,000 shares of common stock at a public offering price of $41.00 per share and pre-funded warrants to purchase 1,000,000 shares of common stock at a public offering price of $40.999 per underlying share.

• Vaxcyte Announces Pricing of $500 Million Public Offering

  4/19/2023

  Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

• Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

  4/17/2023

  Vaxcyte, Inc. announced positive results from the VAX-24 Phase 2 study in adults aged 65 and older, as well as data from the full six-month safety assessment and prespecified pooled immunogenicity analyses from both the Phase 2 study in adults aged 65 and older and the prior Phase 1/2 study in adults aged 18-64.

• Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants - April 17, 2023

  4/17/2023

  Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

• Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

  4/16/2023

  Vaxcyte, Inc. announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies.

• Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

  3/30/2023

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that the first participants were dosed in the Phase 2 study of VAX-24 in healthy infants.

• Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  2/27/2023

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

• Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

  2/21/2023

  Vaxcyte, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s infant Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

• Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

  2/16/2023

  Vaxcyte, Inc. announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023.

• Vaxcyte to Present at the SVB Securities Global Biopharma Conference

  2/7/2023

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

• Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

  1/5/2023

  Vaxcyte, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD), in adults.

• Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

  12/20/2022

  Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) and Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) today jointly announced an option grant agreement through which Vaxcyte acquired an option to access expanded rights to develop and manufacture cell-free extract, among other rights.

• Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/7/2022

  Vaxcyte, Inc. announced financial results for the third quarter ended September 30, 2022 and provided a business update.

• Vaxcyte to Present at Upcoming Investor Conferences

  11/3/2022

  Vaxcyte, Inc. announced today that Company management will participate in and host one-on-one meetings at the following investor conferences.